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ABSTRACT
Introduction: Many studies have found an increased
risk of venous thromboembolism (VTE) associated with
the use of combined hormonal contraceptives, but
various methodologies have been used in the study
design relating to definition of VTE event and the
selection of appropriate cases for analysis. This study
will focus on common oral hormonal contraceptives,
including compositions with cyproterone because of
their contraceptive effect and will perform a number of
sensitivity analyses to compare findings with previous
studies.
Methods and analysis: 2 nested case–control
studies will be based on the general population using
records from UK general practices within the
QResearch and Clinical Practice Research Datalink
databases. Cases will be female patients aged 15–49
with primary VTE diagnosed between 2001 and 2013.
Each case will be matched by age, year of birth and
practice to five female controls, who are alive and
registered with the practice at the time of diagnosis of
the case (index date). Exposure to different hormonal
contraceptives will be defined as at least one
prescription for that contraceptive in the year
before the index date. The effects of duration and the
length of any gap since last use will also be
investigated. Conditional logistic regression will be
applied to calculate ORs adjusted for smoking,
ethnicity, comorbidities and use of other medications.
Possible indications for prescribing hormonal
contraceptives, such as menstrual disorders, acne or
hirsutism will be included in the analyses as
confounding factors. A number of sensitivity analyses
will be carried out.
Ethics and dissemination: The initial protocol
has been reviewed and approved by ISAC (Independent
Scientific Advisory Committee) for Medicine
and Healthcare Products Regulatory Agency Database
Research. The project has also been reviewed by
QResearch and meets the requirements of the Trent
Research Ethics Committee. The results will be
published in a peer-reviewed journal.
INTRODUCTION
An increased risk of thrombosis in users of
hormonal contraceptives has been identiﬁed
by a number of studies, and this has resulted
in British National Formulary (BNF) recom-
mendations1 to consider risk factors for
venous thromboembolism (VTE) before pre-
scribing the drugs and to avoid using them if
two or more risk factors are present. Since
the onset of oral contraceptive use in the
general female population in the 1960s,
studies have demonstrated associations
between the drugs and a range of adverse
side effects, including an increased risk of
VTE. The composition of hormonal contra-
ceptives has, therefore, changed over time. A
‘second generation’ aimed to reduce the
increased VTE risk, lowering the oestrogen
component by using potent testosterone-
derived progestogens.2 A later ‘third-
generation’ was introduced to lower the
androgenic and vascular risk by introducing
progestogens with low androgenic activity3
and to reduce arterial vascular impact.2
Effects on VTE from third-generation
Strengths and limitations of this study
▪ Primary care research databases.
▪ Large size and great statistical power.
▪ A range of sensitivity analyses to compare the
results with other studies.
▪ Results being adjusted for all confounders for
which data are available.
▪ Prescription-based study.
▪ Possible uncertainty in the diagnosis of venous
thromboembolism.
▪ Underestimation of hormonal contraceptive use.
▪ Lack of information on some confounding
factors that might affect the choice of contracep-
tive drug.
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contraceptive use, have, however, been complex, with
some increased risks reported.4
There are a large number of observational studies
looking at the effect of contraceptive drugs on the
general female population, but there are three key
methodological issues which have been handled very dif-
ferently across these. The ﬁrst concerns veriﬁcation of
the VTE diagnosis. Standardised criteria for diagnostic
categories include four levels of veriﬁcation: positive
imaging tests (eg, positive Doppler ultrasound or imped-
ance plethysmography) and subsequent therapy (1: def-
inite VTE), uncertain imaging tests with subsequent
therapy (2: probable VTE), positive imaging tests
without subsequent therapy or negative imaging tests
but with subsequent therapy (3: possible VTE), and
‘typical symptoms’ without conﬁrming tests or therapy
(4: potential VTE).5
To date, observational studies have treated the veriﬁca-
tion of VTE in a number of different ways. An Austrian
study distinguished between conﬁrmed and not con-
ﬁrmed cases, concentrating on cases with deﬁnite and
probable VTE for the main analysis and performing
additional analysis on the sample including possible and
potential VTE cases, which produced statistically identi-
cal results to their main analysis.6 An Israeli study based
on a healthcare provider’s database used clinical records
only without any veriﬁcation.7 A Danish study based on
national healthcare databases used anticoagulation pre-
scriptions for veriﬁcation and produced a stratiﬁed ana-
lysis of conﬁrmed and non-conﬁrmed diagnoses
demonstrating a twofold to threefold higher risk asso-
ciated with VTE in the conﬁrmed group.8 A number of
studies based on electronically collected data included
cases with diagnosis of VTE conﬁrmed with subsequent
anticoagulant prescriptions but without using any diag-
nostic tests.4 9–12 A Dutch study based on hospital and
general practitioners’ (GP) records required conﬁrm-
ation of VTE diagnosis with Doppler ultrasonography.13
These variations in levels of veriﬁcation and differences
in analysis strategy both complicate comparisons of study
ﬁndings.
The second area of variation between studies lies in
sample selection. For example, although women with
oophorectomy, hysterectomy or sterilisation should not
remain in the group potentially exposed to contraceptives,
of the major studies with reference to the no use group
only Lidegaard et al8 mention exclusion of such patients.
As important is the difference in handling of non-
idiopathic cases—those with other potentially important
proximate causes and risk factors. Almost all studies were
aligned in excluding women with previous VTE (as the
studies were focused on incident cases) and the majority8–
10 13 14 in excluding pregnant and postpartum women
(unlikely users of contraceptive drugs and with a higher
risk of VTE), but the handling of non-idiopathic cases
based on morbidities has varied signiﬁcantly.
The study of Farmer et al4 excluded patients with
recent major surgery and trauma, cancer and congenital
heart disease, while the studies of Jick and coauthors9 11
added renal failure, chronic cardiovascular disease,
inﬂammatory or autoimmune conditions and an oper-
ation or major trauma before the diagnosis as exclusion
criteria. The study of Parkin et al10 extended the exclu-
sion list even further with diabetes type I, colitis, systemic
lupus erythematosus, spondylitis, cystic ﬁbrosis, psoriatic
arthritis and coagulation disturbances. The study of
Lidegaard et al,8 however, excluded only those with
selected cancers and coagulation disturbances, while a
number of studies15–18 did not exclude any such
morbidity-related idiopathic cases. A study by
Heinemann et al6 identiﬁed a subgroup of idiopathic
cases and used additional analysis to demonstrate that
the ORs for the selected group were twice those for the
whole study sample.
The third methodological issue involves the related
issues of exposure deﬁnition and reference group selec-
tion. Some studies were based only on current users, esti-
mating the risk associated with use of one drug in
comparison with another,7 9 10 15 16 while others com-
pared current users with the non-exposed group.6 8 18
‘Current use’ has also had a range of deﬁnitions, which
is problematic because the increased risk of VTE in
patients on oral contraceptives decreases after therapy
stops and disappears within 3 months.19 The study of
Heinemann et al6 considered a patient as a current user
for 6 weeks after discontinuation, while the studies of
Jick et al9 and Parkin et al10 extended the period of
current use for only 30 days. The study of Lidegaard
et al8 allowed 4 weeks after the end date of the prescrip-
tion before changing a woman’s exposure status to previ-
ous user, while the study of Gronich et al7 allowed
3 months. Seeger et al15 considered women as current
users only if they had not reached the end date for the
prescription, while in the questionnaire-based
studies16 18 current use was derived from the responses
of participants.
Twenty-six studies based on data up to 2013 contribu-
ted to a recent meta-analysis20 for combined oral contra-
ceptives, which demonstrated a twofold or more
increased risk of VTE in users of any type or generation
of ‘the pill’ compared with non-users. All the studies
listed above were included in the meta-analysis but had a
wide variation in estimates because of their heterogen-
eity of approach, in particular with respect to the deﬁn-
ition of cases, inclusion criteria and reference group
selection and deﬁnition of exposure. This overview
shows that there are no established criteria for selecting
patients for assessment of the VTE risk associated with
use of oral contraceptives. Excluding cases without anti-
coagulant therapy might introduce a selection bias as
doctors may be more likely to start medical treatment in
patients on contraceptive drugs even with mild symp-
toms of VTE.21 Excluding non-idiopathic cases restricts
analysis to relatively healthy patients but does not
remove patients with known risk factors such as
smoking, obesity or other unmeasured lifestyle factors.
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Established risk factors, however, do not prevent doctors
from prescribing contraceptive drugs and their decisions
are affected by all information available to them, so the
question of how inclusive or exclusive the sample should
be is important from a practical point of view.
The proposed nested case–control studies based on
the general female population will investigate the associ-
ation between the use of most common hormonal con-
traceptives and risk of VTE adjusted for indications
other than contraception (polycystic ovarian syndrome
(PCOS) and menstrual disorders), comorbidities affect-
ing prescribing and other confounding factors. In terms
of exclusions and inclusions, the study will perform a
number of sensitivity analyses to make it comparable
with other studies. It will provide an overview of the risks
associated with the currently most common types of oral
contraceptives and increase its power by combining the
results obtained from the two largest electronic medical
records databases, QResearch and Clinical Practice
Research Datalink (CPRD).
METHODS AND ANALYSIS
Data source
This study will use two separate data sources—the
QResearch primary care research database (http://www.
qresearch.org and the CPRD, http://www.cprd.com).
Both consist of routinely collected data from GP clinical
computer systems and each contains information from
around 7% of all UK general practices. The information
recorded on the databases includes patient demograph-
ics (year of birth and sex), characteristics (height,
weight and smoking status), clinical diagnoses, symptoms
and prescribed medications, including repeat prescrip-
tions. Both databases have been created for research
purposes and linked to other sources of information,
such as Hospital Episode Statistics (HES) and Ofﬁce of
National Statistics mortality data. Both have been vali-
dated using other sources of information in the UK,
which has demonstrated their accuracy and complete-
ness.22 Although QResearch has not been validated as
extensively as CPRD, a recent study on risk of cancer
and use of bisphosphonates based on these databases
demonstrated similar prevalence in outcomes and pre-
scribing.23 24 Both databases have been used in previous
studies of VTE associated with prescription
information.10 25
Sample selection
The studies will use records from UK general practices
within the QResearch database and within the CPRD
database. An open cohort of women from each database
will be identiﬁed, all between the age of 15 and 49 years,
registered with the study practices during the study
period between 1 January 2001 and 31 December 2013.
The right censor date will be the earliest of the following
where applicable: date of diagnosis of VTE, date of
death, date of leaving the practice, date of the latest
download of data and study end date. Diagnosis of VTE
will be based on recording in the electronic patient
records using READ codes—the list of READ codes is
presented in table 1.
Within each of these two cohorts we will design two
nested case–control studies with incident cases of VTE
registered during the study period. Cases will be indi-
vidually matched with up to ﬁve female controls with the
same year of birth, age and from the same general prac-
tice. The controls will be selected using incidence
density sampling and allocated an index date, which is
the date on which their matched case was ﬁrst diag-
nosed with VTE.
Table 1 Read codes for VTE used in QResearch and
CPRD data extraction
Read
codes Read description
F051.00 Thrombosis of central nervous system
venous sinuses
F051000 Thrombosis cavernous sinus
F051100 Thrombosis of superior longitudinal sinus
F051200 Thrombosis lateral sinus
F051300 Thrombosis transverse sinus
F051z00 Thrombosis of central nervous system
venous sinus NOS
F423811 Retinal vein thrombosis
G401 Pulmonary embolism
G401-1 Infarction—pulmonary
G401-2 Pulmonary embolus
G4010 Postoperative pulmonary embolus
G676 Non-pyogenic venous sinus thrombosis
G801-1 DVT
G801-2 DVT, leg
G801-3 DVT
G801-99 DVT—leg
G801C DVT of leg related to air travel
G801D Deep vein thrombosis of lower limb
G801D-99 DVT—leg
G801E DVT of leg related to intravenous drug use
G801F DVT of peroneal vein
G820 Budd-Chiari syndrome (hepatic vein
thrombosis)
G820-1 Hepatic vein thrombosis
G822 Embolism and thrombosis of the vena cava
G823 Embolism and thrombosis of the renal vein
G824.00 Axillary vein thrombosis
G825.00 Thrombosis of subclavian vein
G826.00 Thrombosis of internal jugular vein
G827 Thrombosis of external jugular vein
G82y.00 Other embolism and thrombosis
G82z.00 Embolism and thrombosis NOS
G82z0 Venous embolism NOS
G82z1 Venous thrombosis NOS
G82zz00 Embolism and thrombosis NOS
SP122 Postoperative deep vein thrombosis
CPRD, Clinical Practice Research Datalink; DVT, deep vein
thrombosis; NOS, not otherwise specified; VTE, venous
thromboembolism.
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Exclusions
Cases and controls with any previous VTE diagnosis
prior to entry into the study will be excluded. Cases with
anticoagulant prescriptions (BNF 2.8) earlier than
6 weeks prior to the diagnosis will be excluded since this
could indicate a previous VTE, and controls with such
prescriptions before the index date will also be
excluded.
Cases and controls will be excluded from the analysis
if they have conditions preventing use of contraceptives
such as oophorectomy, hysterectomy and sterilisation.
We will also exclude women pregnant at the index date
or in the ﬁrst 3 months after delivery (using pregnancy
codes and an estimated conception date as delivery date
minus 280 days or delivery date minus gestational age if
recorded), because these patients have a higher VTE
risk26 and because it is less likely for breast feeding
women to have been using hormonal contraceptives.
Eligible cases and controls will have at least 1 year of
records prior to the index date.
Exposure
The observational period for assessing exposure for each
patient will be deﬁned as the last year before the index
date.
Exposure to hormonal contraceptives will be based on
all prescriptions for combined hormonal and
progestogen-only contraceptives within the 1 year obser-
vation period (BNF 7.3.1, 7.3.2) and hormonal treat-
ment of acne (co-cyprindiol or cyproterone, from BNF
13.6.2). Cyproterone will be included as a hormonal
contraceptive because it has a similar effect to progesto-
gen on the release of testosterone by ovaries.27 A partici-
pant will be considered as ever exposed if they had at
least one prescription for a hormonal contraceptive.
The main focus will be on combined oral contracep-
tives. We will consider the compositions containing levo-
norgestrel, desogestrel, norgestimate, norethisterone,
gestodene, drospirenone and cyproterone. As an associ-
ation of increased risk of VTE in transdermal versus oral
contraceptive users has been found,28 women exposed
to non-oral combined contraceptives will be identiﬁed
and kept in the analysis. Progestogen-only drugs are not
expected to be associated with an increased risk of VTE8
but will be kept in the analysis for comparison purposes,
with oral and non-oral preparations as two different
types of exposure. For all analyses non-users of hormo-
nal contraceptives in the previous year will be the refer-
ence category.
Numbers permitting, dosages of oestrogen, 20 or
30 mg and more of ethinylestradiol, will be analysed for
the most common compositions: norethisterone, deso-
gestrel and gestodene.
The duration of exposure will be assessed by calculat-
ing the number of days prescribed within the previous
year. If the gap between the end of one prescription and
the start of the next is not more than 30 days, use will be
considered as continuous and the duration of the
prescriptions will be summed. If a gap between prescrip-
tions is more than 30 days only the latest period of
exposure will be considered.
Recency of use will be analysed by calculating the gap
in days between the estimated date for the last use and
the index date, and categorising it as: current use (using
drugs at the index date or the last use was no more than
28 days before the index date), past use (last use
between 29 and 365 days before the index date) and no
use in last year. If a woman was exposed to more than
one oral contraceptive in the 28 days before the index
date, only the latest received drug will be analysed, and
a variable indicating whether or not women had
switched in the last 28 days will be included in the
analysis.
We will estimate the effect of the duration of the last
exposure by categorising it as up to 84 days (short term)
and more than 84 days (long term). The cut point of
84 days (12 weeks) is chosen because VTE risk decreases
after 3 months of exposure19 and 84 days is the most
common length of a contraceptive prescription. We will
combine recency and duration of exposure to give four
categories for each drug exposure: current use with
short-term exposure, current use with long-term expos-
ure, past exposure and no use in the last year.
Confounding factors
All analyses will be adjusted for confounders established
as risk factors for VTE because they are listed in
National Health Service (NHS) guidelines29 and affect
doctors’ decisions about prescribing hormonal contra-
ceptives. The list will include comorbidities associated
with increased risk of VTE30: cancer, congestive cardiac
failure, varicose veins, cardiovascular disease, rheuma-
toid arthritis, systemic lupus erythematosus, chronic
renal disease, asthma, chronic obstructive pulmonary
disease, Crohn’s or ulcerative colitis and coagulation dis-
turbances (Leiden factor V, protein C and S deﬁcien-
cies).31 Particular medical events will also be included if
recorded in the past 6 months prior to the index date:
acute infections, surgery, hospitalisation, leg or hip frac-
ture.12 30 Patients with these comorbidities and condi-
tions will be identiﬁed as non-idiopathic cases for
further sensitivity analysis.
Other confounders—patients’ characteristics mea-
sured at the closest date before the index date—will be:
body mass index (BMI, continuous variable)7, smoking
status (current smoker: light 1–9 cigarettes/day, medium
10–19, heavy 20 or more, ex-smoker and non-smoker)32,
alcohol consumption and ethnicity (White, Black, Asian,
other).33
As there is likely to be a large group of women taking
hormonal contraceptives for treatment of PCOS, this
condition will also be included because of associations
with increased risk of VTE.34 Other reasons for com-
bined hormonal contraceptive use, such as acne, hirsut-
ism and menstrual disorders, will be included into
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analysis if the OR for at least one of the exposure vari-
ables is changed by more than 10%.
Statistical analysis
Conditional logistic regression will be used to estimate
ORs with 95% CIs for VTE. The initial analysis model
will determine the unadjusted ORs for VTE associated
with the key exposure variables of interest (speciﬁc types
of drugs, recency of use and duration and dose). A mul-
tivariable model will determine the OR for VTE asso-
ciated with hormonal contraceptive prescriptions,
adjusted for the confounding variables listed above. The
main analyses will be run on all cases with VTE identi-
ﬁed from the general practice data and their matched
controls. A sensitivity analysis will be run on the sub-
group of cases and their matched controls where the
case diagnosis is supported by thrombolytic prescriptions
in the 6 weeks before or after the VTE diagnosis. A
second sensitivity analysis will be run on idiopathic cases
and their controls, excluding from the analysis all cases
and controls with medical conditions and recent events
established as VTE risk factors. A third sensitivity analysis
will be run on all non-idiopathic cases and controls.
For practices linked to HES data another sensitivity
analysis will be run. New cases of VTE identiﬁed in HES
will be added to the analysis and controls with VTE
recorded in HES prior to the index date will be
removed.
As the proportion of women using contraceptive
clinics (where the data on contraception is not recorded
in their GP records) is higher (10%) for a younger
group (15–24 years) compared with 3% for women
25 years and older,35 separate subgroup analyses will be
run on the older and younger group, and we will carry
out a test for interaction with age.
As BMI, smoking status and alcohol consumption may
be important confounders but have non-negligible
numbers of missing data, multiple imputation will be
used to impute missing values.36 Ten imputed datasets
will be created. Index year, case/control status, age,
years of records, potential confounders and exposure to
hormonal contraceptives and other drugs, will be
included in the imputation model. The distribution for
BMI will be assessed and, if not normal, a transform-
ation will be carried out prior to inclusion in the imput-
ation model. Characteristics of women with missing
values and with complete data will be compared to
assess whether it is plausible that data are missing at
random. A sensitivity analysis restricted to women
without missing data for BMI, smoking status and
alcohol consumption will also be performed.
The nested case–control studies for QResearch and
CPRD will be carried out separately and in exactly the
same way, selecting the same confounders and running
the same procedures. All observations will be from
general practices in the UK, from the same time period,
with similar exposures and using similar methods for
recording outcomes. The sizes of the studies are also
expected to be similar. Any differences in associations
observed across the databases are likely to be caused
only by sampling variation. The results from the two
studies will then be combined using the method of
Mantel and Haenszel for ﬁxed effect models.
A 1% level of statistical signiﬁcance will be used to
allow for multiple comparisons. Stata V.12 will be used
for all the analyses.
Sample size calculation
All eligible cases from QResearch and CPRD will be
used. According to the Ofﬁce for National Statistics,
combined contraceptives are used by 25% of women
aged 15–49 in the UK.37 For an individual drug with
exposure of 5%, 2115 cases and 10 575 controls will be
needed to detect a clinically important OR of 1.5 at a
signiﬁcance level of 1% with 90% power. For rarer com-
positions such as drospirenone or cyproterone with
exposure of 1% and a clinically important OR of 2.0,
2882 cases and 14 410 controls will be needed. The
numbers of cases from QResearch and CPRD are
expected to be fairly similar. The January 2014 version
of CPRD contains 8673 cases with ﬁrst time VTE
recorded between 2001 and 2013. After removing preg-
nant and postpartum women, cases with previous anti-
coagulant prescriptions and cases with less than a year of
medical records, a sample of 5920 cases will be available
for analysis in CPRD.
DISCUSSION
This is an observational study based on routinely col-
lected data from two large primary care research data-
bases and will have the strengths and limitations
common to all such studies. By combining results from
two databases, the study will have greater statistical
power than previous studies. It will allow analyses to be
carried out investigating the effects of the recency and
duration of use for the most commonly used hormonal
contraceptives. Because the data on prescriptions and
potential confounding variables are routinely and pro-
spectively collected and recorded before the index date,
the study will be free from recall bias. Similarly, as all eli-
gible cases and randomly selected controls will be
included, there should be no selection bias.
The study will conduct a number of sensitivity analyses
to address conﬂicting methodological issues giving the
reader an opportunity to decide which estimates are the
most valid.
The limitations of the study will include possible
uncertainty in VTE diagnosis. A systematic review based
on General Practice Research Database (GPRD) valid-
ation studies has reported that, on average, 85% of diag-
noses of circulatory system problems recorded on the
GP electronic record were conﬁrmed from other data
sources.38 Lawrenson et al39 looked speciﬁcally at VTE
validation and found that 84% of the diagnoses were
supported by hospitalisation or death certiﬁcate. Any
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misclassiﬁcation (assuming it is non-differential between
cases and controls) will result in underestimation of asso-
ciations with hormonal contraceptives, shifting the ORs
towards unity. The sensitivity analysis on validated diag-
nosis of VTE along with descriptive statistics will address
issues about differential attention to different types of
contraceptives raised in the Danish study.8
Another limitation is potential underestimation of hor-
monal contraceptive use. Apart from the GP, hormonal
contraceptives are available from other NHS services such
as family planning or contraceptive clinics. According to
the Health & Social Care Information Centre,35 approxi-
mately 0.6 million women in England are supplied with
hormonal contraceptives from contraceptive clinics, which
represents about 5% of the targeted population. Although
a survey of contraceptive services use in Britain40 reported
that only 59% of responding women would use general
practice and 15% would use contraceptive clinics, the
response rate of the survey was only 65% and the actual
proportions might be smaller. From currently available
CPRD data, overall use of hormonal contraceptives based
on GP prescriptions is about 50%, so excess of use from
other sources will be considered minor.
Other limitations are also common to any general
practice database. Information on certain risk factors
such as level of physical activity or use of air travel is not
reliably recorded so these factors cannot be included in
the analyses. Important confounders such as smoking or
BMI have non-negligible amounts of missing data so
these will be imputed.
The results of this study will help to establish risks of
VTE associated with different oral hormonal contracep-
tive drugs.
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